Long‐term adverse effects of paracetamol – a review

British Journal of Clinical Pharmacology - Tập 84 Số 10 - Trang 2218-2230 - 2018
Jame McCrae1, Emma E. Morrison1, I. MacIntyre1, James W. Dear1, David J. Webb1
1BHF Centre of Research Excellence (CoRE) Queen's Medical Research Institute, Pharmacology, Toxicology & Therapeutics Edinburgh UK

Tóm tắt

Paracetamol (acetaminophen) is the most commonly used drug in the world, with a long record of use in acute and chronic pain. In recent years, the benefits of paracetamol use in chronic conditions has been questioned, notably in the areas of osteoarthritis and lower back pain. Over the same period, concerns over the long‐term adverse effects of paracetamol use have increased, initially in the field of hypertension, but more recently in other areas as well. The evidence base for the adverse effects of chronic paracetamol use consists of many cohort and observational studies, with few randomized controlled trials, many of which contradict each other, so these studies must be interpreted with caution. Nevertheless, there are some areas where the evidence for harm is more robust, and if a clinician is starting paracetamol with the expectation of chronic use it might be advisable to discuss these side effects with patients beforehand. In particular, an increased risk of gastrointestinal bleeding and a small (~4 mmHg) increase in systolic blood pressure are adverse effects for which the evidence is particularly strong, and which show a degree of dose dependence. As our estimation of the benefits decreases, an accurate assessment of the harms is ever more important. The present review summarizes the current evidence on the harms associated with chronic paracetamol use, focusing on cardiovascular disease, asthma and renal injury, and the effects of in utero exposure.

Từ khóa


Tài liệu tham khảo

10.1002/cber.18780110151

Jefferies S, 2012, Paracetamol in critical illness: a review, Crit Care Resusc, 14, 74

Von Mering J, 1893, Beitrage zur Kenntniss der antipyretica, Ther Monatsch, 7, 577

10.1111/1753-6405.12252

10.1111/j.1527-3458.2006.00250.x

10.1136/annrheumdis-2014-206914

World Health Organization.Cancer pain relief: with a guide to opioid availability[online]. Available athttp://www.who.int/iris/handle/10665/37896(last accessed 8 January 2018).

Paracetamol 500 mg tablets – summary of product characteristics (SmPC) ‐ (eMC) [online].http://medicines.org.uk. Available athttps://www.medicines.org.uk/emc/product/4195(last accessed 8 January 2018).

SaragiottoBT MachadoGC FerreiraML PinheiroMB Abdel ShaheedC MaherCG.Paracetamol for low back pain. In: Cochrane Database of Systematic Reviews [online]. Available athttp://doi.wiley.com/10.1002/14651858.CD012230(last accessed 8 January 2018).

TowheedT MaxwellL JuddM CattonM HochbergMC WellsGA.Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews [online]. Available athttp://doi.wiley.com/10.1002/14651858.CD004257.pub2(last accessed 8 January 2018).

10.1016/j.joca.2010.01.013

10.1136/ard.2003.018531

National Institute for Health and Care Excellence.Osteoarthritis: care and management[online]. Available athttps://www.nice.org.uk/guidance/cg177?unlid=124915017201652233315(last accessed 8 January 2018).

PriceC.NICE forced into U‐turn on advice to avoid paracetamol in osteoarthritis [online]. Pulse Today. Available athttp://www.pulsetoday.co.uk/clinical/more‐clinical‐areas/musculoskeletal/nice‐forced‐into‐u‐turn‐on‐advice‐to‐avoid‐paracetamol‐in‐osteoarthritis/20005837.article(last accessed 8 January 2018).

10.3109/15360288.2015.1037521

10.1136/bmj.j790

10.1002/j.1532-2149.2014.496.x

10.1136/bmj.d2218

10.1007/s10787-013-0172-x

10.1016/j.joen.2015.01.024

10.1097/00045391-200501000-00008

10.1074/jbc.M501489200

10.1371/journal.pone.0012748

10.1038/ncomms1559

10.1371/journal.pone.0113841

10.1097/FPC.0000000000000150

10.1161/CIRCULATIONAHA.105.595793

10.1111/bcp.12032

10.1016/S0002-9343(98)00091-6

10.3109/10641968409039582

National Institute for Health and Care Excellence.Hypertension in adults: diagnosis and management[online]. Available athttps://www.nice.org.uk/guidance/CG127(last accessed 8 January 2018).

10.1161/01.HYP.0000035856.77718.DA

10.1001/archinte.162.19.2204

10.1001/archinte.167.4.394

10.1001/archinte.165.16.1903

10.1097/HJH.0b013e328360f6f8

10.1161/01.HYP.0000177437.07240.70

10.1161/CIRCULATIONAHA.110.956490

10.1161/HYPERTENSIONAHA.114.04945

10.1136/adc.65.8.826

10.1136/bmj.322.7302.1591

Global Asthma Network.The global asthma report [online]. Available athttp://www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf(last accessed 8 January 2018).

10.1016/S1081-1206(10)63127-4

10.1378/chest.09-0865

10.1016/j.aller.2012.07.012

10.1111/j.1365-2222.2009.03378.x

10.1080/02770900802165998

10.1164/rccm.200304-596OC

10.1164/rccm.200409-1269OC

10.1183/09031936.00.16581700

10.1136/thorax.55.4.266

10.1136/archdischild-2012-303043

10.1164/rccm.200802-309OC

10.1016/j.jaci.2009.11.039

10.1136/bmj.c4616

10.1164/rccm.201006-0989OC

10.1007/s00228-012-1463-7

10.1038/clpt.1987.50

10.1002/hep.1840190511

10.1016/j.prrv.2012.04.004

10.1007/s11882-009-0024-3

10.1378/chest.127.2.604

10.1007/s004320000228

10.1046/j.1365-2710.2003.00492.x

10.1378/chest.118.5.1470

10.1016/0091-6749(89)90174-7

10.1016/S0091-6749(95)70290-3

10.1016/j.iac.2004.03.001

10.1007/s11882-004-0037-x

10.1136/bmjopen-2013-004324

10.1056/NEJMoa1515990

10.1136/adc.74.2.164

10.1177/014107688007301004

10.1136/bmj.h3705

10.1007/978-3-642-00663-0_12

10.1136/ard.2011.154047

10.1007/s11096-004-9008-5

10.1517/14740338.3.4.269

10.1016/0895-4356(95)00539-0

10.1046/j.1365-2125.2002.01636.x

10.1097/00001648-200109000-00018

10.1111/j.1742-7843.2006.pto_248.x

10.1111/j.1572-0241.2008.01811.x

10.1111/j.1572-0241.1998.00327.x

10.1161/STROKEAHA.115.012091

10.1046/j.1365-2125.2000.00167.x

10.1542/peds.2009-3352

Giboney PT, 2016, Mildly elevated liver transaminase levels in the asymptomatic patient, Am Fam Physician, 71, 1105

10.1186/2050-6511-15-39

10.1592/phco.27.9.1219

10.1111/bcp.12802

Guengerich FP, 1991, Comparison of levels of several human microsomal cytochrome P‐450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples, J Pharmacol Exp Ther, 256, 1189

10.1038/clpt.1983.14

10.1111/j.1365-2125.1981.tb01193.x

10.1097/01.mjt.0000140216.40700.95

Mahe I, 2006, Interaction between paracetamol and warfarin in patients: a double‐blind, placebo‐controlled, randomized study, Haematologica, 91, 1621

Worriax JD, 2007, Clinical inquiries. Alcoholic liver disease: is acetaminophen safe?, J Fam Pract, 56, 673

10.1111/j.1365-2036.2007.03503.x

10.1093/qjmed/hcr098

10.1097/00045391-200203000-00009

10.1007/BF03160941

10.1002/hep.20948

10.1080/20014091111677

10.1002/j.1875-9114.1997.tb03721.x

10.1681/ASN.V6148

10.1136/jcp.34.11.1255

10.1056/NEJM199802123380707

10.2215/CJN.04901107

10.1111/j.1365-2125.1980.tb01812.x

10.1056/NEJM199412223312502

10.1046/j.1523-1755.2000.00410.x

10.1136/bmjopen-2013-004365

10.1016/S1734-1140(12)70847-2

Collins E, 1981, Maternal and fetal effects of acetaminophen and salicylates in pregnancy, Obstet Gynecol, 58, 57s

Levy G, 1975, Letter: evidence of placental transfer of acetaminophen, Pediatrics, 55, 895, 10.1542/peds.55.6.895

10.1016/j.curtheres.2014.12.001

10.1016/j.ajog.2007.08.040

10.1093/ije/dyp151

10.1093/ije/dyt183

10.1001/jamapediatrics.2013.4914

10.1002/aur.1591

Avella‐Garcia CB, 2016, Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms, Int J Epidemiol, 45, 1987

10.1093/toxsci/kft329

10.1016/j.neubiorev.2014.03.012

10.1016/j.jhep.2014.12.020

10.1136/thoraxjnl-2014-205280

10.1136/thorax.57.11.958

10.1093/ije/dyn070

10.1093/ije/dyv366

10.1046/j.1365-2222.1999.00662.x

10.1093/ije/28.4.723

10.1371/journal.pone.0135775

10.1016/j.jaci.2014.07.065

10.1093/humupd/dmm027

10.1172/JCI34241

10.1093/humrep/deq323

10.1126/scitranslmed.aaa4097

10.1289/EHP2307

10.1097/EDE.0b013e3181f20bed

10.1093/humrep/der474

10.1097/EDE.0b013e31821eca69

10.1093/humrep/dew196

10.1111/j.1479-828X.1991.tb02816.x

10.1097/AOG.0b013e3181c52616

10.1111/j.1365-2605.2011.01211.x

10.1002/ppul.22881

10.1111/ppe.12082

10.1542/peds.2013-3898

10.1038/nrendo.2015.106

10.1093/nar/gkx1121

10.1111/bph.13884

10.1111/bph.13877

10.1111/bph.13878

Thông tin
Thông tin xuất bản

British Journal of Clinical Pharmacology

Tập 84 Số 10

2218-2230

Thông tin tác giả